Development of oral microencapsulated forms for delivering viral vaccines
- PMID: 12901577
- DOI: 10.1586/14760584.1.3.385
Development of oral microencapsulated forms for delivering viral vaccines
Abstract
Rapid development in biotechnology during the last decade has allowed novel ideas in the development of antiviral vaccines to be considered and provides interesting technological approaches to their realization. Designing of microencapsulated forms for delivering bacterial and viral antigens or antigenic complexes using biodegradable biopolymers is an important novel direction. This approach involves the production of polymeric spherical particles with a diameter of 1 microm to 3 mm, containing isolated viral antigens or whole viral particles. Microencapsulated antigens administered orally are protected from low pH values of the gastric juice, bile acids, their salts and proteolytic enzymes of the gastrointestinal tract. The ability to drastically potentiate the immune response to encapsulated antigens, together with the ability to penetrate into the intestinal and respiratory mucosae upon oral and tracheal administrations, respectively, with induction of local and systemic immune reactions are the special merits of such polymers. However, the majority of data on microencapsulated viral vaccines has so far been obtained in animal models, as well as a limited number of studies on the protective effect they elicit. Certain success in the development of vaccines against a number of human viral infections, such as hepatitis B, cytomegalovirus and rotavirus, gives hope to successful completion of this research. Presumably, such vaccines will be safe and innocuous, simple in administration and capable of inducing both the systemic and local immune responses at the primary portal of viral infection.
Similar articles
-
Oral delivery of poly(lactide-co-glycolide) encapsulated vaccines.Behring Inst Mitt. 1997 Feb;(98):220-8. Behring Inst Mitt. 1997. PMID: 9382743 Review.
-
Oral delivery of micro-encapsulated DNA vaccines.Dev Biol Stand. 1998;92:149-55. Dev Biol Stand. 1998. PMID: 9554269
-
Enhancement of T helper type 1 immune responses against hepatitis B virus core antigen by PLGA nanoparticle vaccine delivery.J Control Release. 2005 Jan 20;102(1):85-99. doi: 10.1016/j.jconrel.2004.09.014. J Control Release. 2005. PMID: 15653136
-
Mucosal or systemic administration of rE2 glycoprotein antigen loaded PLGA microspheres.Int J Pharm. 2009 May 21;373(1-2):16-23. doi: 10.1016/j.ijpharm.2009.01.020. Epub 2009 Feb 4. Int J Pharm. 2009. PMID: 19429284
-
Mucosal delivery of vaccine antigens and its advantages in pediatrics.Adv Drug Deliv Rev. 2006 Apr 20;58(1):52-67. doi: 10.1016/j.addr.2006.01.002. Epub 2006 Mar 3. Adv Drug Deliv Rev. 2006. PMID: 16516335 Review.
Cited by
-
Nasal Nanovaccines for SARS-CoV-2 to Address COVID-19.Vaccines (Basel). 2022 Mar 8;10(3):405. doi: 10.3390/vaccines10030405. Vaccines (Basel). 2022. PMID: 35335037 Free PMC article. Review.
-
Microencapsulation of bacteriophage felix O1 into chitosan-alginate microspheres for oral delivery.Appl Environ Microbiol. 2008 Aug;74(15):4799-805. doi: 10.1128/AEM.00246-08. Epub 2008 May 30. Appl Environ Microbiol. 2008. PMID: 18515488 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources